Enterococci have become important nosocomial pathogens world‑wide and are associated with a high mortality. The treatment of these infections poses a great challenge due to the inherent resistance of Enterococci to many antibiotics. Infections by Enterococci have traditionally been treated with cell wall active agents in combination with an aminoglycoside; however, the emergence of high level resistance to aminoglycosides (HLAR), beta lactam antibiotics and to vancomycin by some strains, together with association of HLAR with the multidrug resistance has led to failure of synergistic effects of combination therapy.
Select your language of interest to view the total content in your interested language
Annals of Medical and Health Sciences Research received 15898 citations as per google scholar report